Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Rev Esp Patol ; 56(4): 233-242, 2023.
Artigo em Espanhol | MEDLINE | ID: mdl-37879820

RESUMO

INTRODUCTION: Lung cancer is the leading cause of cancer death in our country. Non-small cell lung cancer (NSCLC) represents the paradigm of personalized medicine. The main objective of this study is analysing the distribution of the most frequently described clinically significant variants in NSCLC, in our environment. MATERIAL AND METHODS: We studied the immunohistochemical expression of TTF1, p40 and PD-L1 and the genetic variants frequency using Next-Generation Sequencing (NGS) with a panel of 52 genes, in 174 NSCLC paraffin-embedded samples in 169 patients (111 men and 52 women) from the province of Cádiz. RESULTS: The immunohistochemical expression of TTF1, p40 and PD-L1 was positive in 87%, 0% and 46% in adenocarcinoma, and 0%, 100% and 41% in squamous cell carcinoma. In NGS, the most common single nucleotide variants (SNVs) were KRAS (36%), EGFR (14%), BRAF (10%), PIK3CA (8%), and MET (3%). The most frequent copy number variants (CNVs) were amplifications in NF1 (30%), EGFR (18%), CCND1 (9%), MYC (9%) and KRAS (7%). In women, SNV in EGFR are more frequent than in men (P<.0001). Adenocarcinoma is the most frequent histological type with SNV in KRAS (P=.007361) or in EGFR (P<.0001). Gene fusions were detected in 16 patients (9.47%), in 9 cases in the MET gene. CONCLUSIONS: We detected associations, not described so far, between immunohistochemical expression and specific gene variants, which could have an impact on the treatment of NSCLC patients.


Assuntos
Adenocarcinoma , Carcinoma Pulmonar de Células não Pequenas , Neoplasias Pulmonares , Masculino , Humanos , Feminino , Carcinoma Pulmonar de Células não Pequenas/genética , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/patologia , Antígeno B7-H1 , Proteínas Proto-Oncogênicas p21(ras) , Adenocarcinoma/genética , Receptores ErbB/genética
2.
Thyroid ; 33(9): 1078-1089, 2023 09.
Artigo em Inglês | MEDLINE | ID: mdl-37450344

RESUMO

Purpose: The aim of this study was to validate the new European Organisation for Research and Treatment of Cancer Quality of Life Thyroid Cancer Module (EORTC QLQ-THY34). Methods: We enrolled 437 thyroid cancer patients from 17 countries. One group (n = 303), undergoing treatment or best supportive care, completed the questionnaires at three time points (before therapy [t1], 6 weeks later [t2], and 6 months after t2 [t3]). A second group (survivors ≥2 years after diagnosis, n = 134) completed it at a random baseline time point and a second time 1 week later. We determined internal consistency (using Cronbach's alpha), the scale structure (with confirmatory factor analysis), and discriminant validity (using known-group comparisons). Group 1 data were used to assess responsiveness and group 2 data to determine test-retest reliability using intra-class correlations (ICC). Results: All 34 items fulfilled the criteria to be kept in the questionnaire. Cronbach's alpha was >0.70 in 8 of the 9 multi-item scales. All standardized factor loadings exceeded 0.40, confirming the proposed scale structure. The ICC was >0.70 in all scales expressing good test-retest reliability. Differences in scale scores between patients with different histology were >5 points in all scales. In all but one of the pre-specified scales (Dry Mouth), changes over time were ≥|4| points between at least two time points. Conclusion: The EORTC QLQ-THY34 with its 9 multi-item and 8 single-item scales is a reliable and valid tool to measure quality of life in thyroid cancer patients and can be used in future trials and studies.


Assuntos
Qualidade de Vida , Neoplasias da Glândula Tireoide , Humanos , Reprodutibilidade dos Testes , Psicometria , Inquéritos e Questionários , Neoplasias da Glândula Tireoide/terapia
3.
Curr Neurol Neurosci Rep ; 21(3): 8, 2021 02 09.
Artigo em Inglês | MEDLINE | ID: mdl-33564903

RESUMO

PURPOSE OF REVIEW: Since the advent of next-generation sequencing, the number of genes associated with dystonia has been growing exponentially. We provide here a comprehensive review of the latest genetic discoveries in the field of dystonia and discuss how the growing knowledge of biology underlying monogenic dystonias may influence and challenge current classification systems. RECENT FINDINGS: Pathogenic variants in genes without previously confirmed roles in human disease have been identified in subjects affected by isolated or combined dystonia (KMT2B, VPS16, HPCA, KCTD17, DNAJC12, SLC18A2) and complex dystonia (SQSTM1, IRF2BPL, YY1, VPS41). Importantly, the classical distinction between isolated and combined dystonias has become harder to sustain since many genes have been shown to determine multiple dystonic presentations (e.g., ANO3, GNAL, ADCY5, and ATP1A3). In addition, a growing number of genes initially linked to other neurological phenotypes, such as developmental delay, epilepsy, or ataxia, are now recognized to cause prominent dystonia, occasionally in an isolated fashion (e.g., GNAO1, GNB1, SCN8A, RHOBTB2, and COQ8A). Finally, emerging analyses suggest biological convergence of genes linked to different dystonic phenotypes. While our knowledge on the genetic basis of monogenic dystonias has tremendously grown, their clinical boundaries are becoming increasingly blurry. The current phenotype-based classification may not reflect the molecular structure of the disease, urging the need for new systems based on shared biological pathways among dystonia-linked genes.


Assuntos
Distonia , Distúrbios Distônicos , Anoctaminas , Proteínas de Transporte , Distonia/genética , Distúrbios Distônicos/genética , Subunidades alfa Gi-Go de Proteínas de Ligação ao GTP , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Mutação , Proteínas Nucleares , Fenótipo , ATPase Trocadora de Sódio-Potássio
4.
Salud(i)ciencia (Impresa) ; 16(8): 864-868, jul. 2009. ilus
Artigo em Espanhol | LILACS | ID: lil-599373

RESUMO

Introducción: La patología del tracto urinario superior supone un reto diagnóstico para el urólogo. La aparición de nuevo hardware y software de adquisición y procesamiento de imágenes de tomografía computarizada (TC) ha hecho posible el desarrollo de técnicas como la que presentamos en este estudio. Material y métodos: Entre enero de 2005 y agosto de 2007 hemos incluido 57 urografías por tomografía computarizada (Uro-TC) realizadas en nuestro centro a pacientes con enfermedades del tracto urinario superior. Recogemos las indicaciones, los diagnósticos y comparamos los valores de validez interna y externa de la prueba con los de otras exploraciones radiológicas. Resultados: Realizamos un total de 57 exploraciones a 56 pacientes con edades entre los 38 y los 84 años en las que diagnosticamos 21 litiasis, 8 neoformaciones uroteliales, 2 pélvicas, 3 ureterales y 3 vesicales. En 6 pacientes con ureterohidronefrosis de etiología incierta en otras exploraciones conseguimos dilucidar la causa de la obstrucción. Diagnosticamos 2 litiasis durante el seguimiento de pacientes portadores de derivaciones urinarias, así como 5 casos de estenosis benigna. En 11 pacientes se diagnosticaron diferentes malformaciones congénitas. Los valores de validez interna de la prueba fueron superiores a los de las pruebas de imagen usadas convencionalmente para el diagnóstico de trastornos del tracto urinario superior. Conclusiones: La Uro-TC es una prueba eficiente, que está al alcance de la mayoría de centros en los que se disponga de la tecnología necesaria. Permite en casos seleccionados optimizar recursos sanitarios y agilizar el diagnóstico de la enfermedad urológica.


Assuntos
Humanos , Masculino , Adulto , Feminino , Pessoa de Meia-Idade , Ultrassonografia , Endoscopia/estatística & dados numéricos , Endoscopia/instrumentação , Endoscopia , Doenças Urológicas/diagnóstico
5.
Rev. cuba. farm ; 37(2)mayo.-ago. 2003. tab
Artigo em Espanhol | LILACS | ID: lil-386923

RESUMO

Diferentes concentraciones de 6 extractos de corteza de Pinus caribaea Morelet var. caribaea se enfrentaron a 2 dosis de virus en un ensayo in vitro, sobre células MT4; la actividad antiviral se midió por ensayo inmunoenzimático de captura de proteína 24 del virus. Todas las fracciones mostraron actividad citotóxica moderada y solo una fue altamente tóxica. La fracción 02 mostró un alto porcentaje de inhibición de la replicación viral, en relación con la dosis viral y la concentración del producto, con un índice de selectividad de 100, pero son necesarios estudios adicionales sobre la identificación de la estructura química para definir el mecanismo de acción del producto


Assuntos
Antivirais , HIV-1 , Pinus , Taninos , Replicação Viral
6.
Rev. cuba. farm ; 33(2): 89-97, mayo-ago. 1999. tab, ilus
Artigo em Espanhol | LILACS | ID: lil-270989

RESUMO

Se estudió la inactivación del virus herpes simple humano tipo 1 como modelo de virus ADN envueltos, durante las etapas de producción de las inmunoglobulinas intramuscular e intravenosa y la albúmina humana, las etapas del método de fraccionamiento alcohólico para la obtención de estos productos, así como los métodos de remoción y/o inactivación introducidos en el proceso de manufactura, pasteurización y cromatografía de intercambio iónico. El virus se cuantificó por efecto citopático. La obtención de valores de reducción acumulativos reportados en este trabajo demuestran que el método de fraccionamiento alcohólico utilizado en Cuba como variante del método de Cohn-Oncley, combinando métodos de inactivación/remoción, produce un nivel de inactivación de virus ADN envueltos que garantiza una alta seguridad biológica de estos productos para su uso en humanos


Assuntos
DNA Viral , Composição de Medicamentos , Herpesvirus Humano 1 , Imunoglobulinas , Albumina Sérica
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA